Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02725268 · ClinicalTrials.gov registry record · Phase 2
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 241
- Enrollment target
NCT02725268 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 241 participants.
The verdict
NCT02725268, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 241 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
Interventions
- DRUG Paclitaxel
- DRUG Sapanisertib
- DRUG MLN1117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02725268
The ClinicalTrials.gov registry entry for NCT02725268 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT02725268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02725268 about?
NCT02725268 is a clinical study titled "A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer". The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
What is the current status of trial NCT02725268?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2016-04-01. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT02725268?
The interventions under investigation include: Paclitaxel (DRUG), Sapanisertib (DRUG), MLN1117 (DRUG).
Who is sponsoring clinical trial NCT02725268?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.